The increasing role of pharmacogenetics in the treatment of gastrointestinal cancers

Gastrointestinal Cancer Research

Volumn 3, Issue 5, 2009, Pages 197-203

  Yalçin, Şuayib ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

5',3' NUCLEOTIDASE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARRIER PROTEIN; CETUXIMAB; CISPLATIN; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE PHOSPHATE DEAMINASE; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA TOPOISOMERASE; DRUG RECEPTOR; ENZYME; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; INTERLEUKIN 8; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; PANITUMUMAB; RIBONUCLEOTIDE REDUCTASE; THYMIDYLATE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TRANSFORMING GROWTH FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANUS CANCER; COLORECTAL CANCER; COMORBIDITY; CREATININE CLEARANCE; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; DRUG EXCRETION; DRUG METABOLISM; DRUG RESPONSE; DRUG TRANSPORT; DRUG USE; FOOD AND DRUG ADMINISTRATION; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; GILBERT DISEASE; GLUCURONIDATION; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; METABOLITE; NEUTROPENIA; PANCREAS CANCER; PANCREAS CARCINOMA; PHARMACOGENETICS; REVIEW; STOMACH CANCER; UNSPECIFIED SIDE EFFECT;

EID: 77953440835     PISSN: 19347820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Parkin MD, Bray F, Ferlay J, et al: Global Cancer Statistics, 2002. CA Cancer J Clin 55:74 -108, 2005
2. Yalcin S, Oksuzoglu B, Tekuzman G, et al: Bi-weekly irinotecan (CPT-11) plus bolus 5-fluourouracl (5-FU) and folinic acid in patients with advanced stage colorectal cancer (ACRC). Jpn J Clin Oncol 33:580-583, 2003
3. Aksoy S, Karaca B, Dincer M, et al: Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient. vasospasm in a colon cancer patient. Ann Pharmacother 39:573-574, 2005
4. Yong WP, Innocenti F, Ratain MJ: The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 62:35-46, 2006
5. Vesell ES: Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 41:535-552, 1989
6. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol 16:3537-3541,1998
7. Daher GC, Harris BE, Diasio RB: Metabolism of pyrimidine analogues and their nucleosides. Pharmacol Ther 48:189-222, 1990
8. Diasio RB: Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology. Oncology 15:21-26, 2001
9. Fleming RA, Milano GA, Gaspard MH, et al: Dihydropyrimidine dehydrogenase activity in cancer patients. Eur J Cancer 29A:740-744, 1993
10. Milano G, Etienne MC, Pierrefite V, et al: Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79:627-630, 1999
11. Uetake H, Ichikawa W, Takechi T, et al: Relationship between intratumoral dihydropyrimidine dehydrogenase activity and gene expression in human colorectal cancer. Clin Cancer Res 5:2836-2839, 1999
12. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics newly identified deficient patients and clinical implications in 5-fluorouracil in cancer patients. Cancer Res 53:5433-5438, 1993
13. Wei X, Elizondo G, Sapone A, et al: Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51:391-400, 1998
14. Mattison L, Soong R, Diasio R: Implications of di hydropyrimidine dehydrogenase on 5FU pharmacogenetics and pharmacogenomics. Pharmacogenomics 3:485-491, 2002
15. Ridge S, Sludden J, Wei X, et al: Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer 77:497, 1998
16. Miller CR, McLeod HL: Pharmacogenomics of cancer chemotherapy-induced toxicity. Support Oncol 5:9-14, 2007
17. Johnston PG, Lenz HJ, Leichman CG, et al: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 55(7): 1407-1412, 1995
18. Kidd EA, Yu J, Li X, et al: Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. Clin Cancer Res 11:2612-2619, 2005
19. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al: Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 1:65-70, 2001
20. Marsh S, McKay JA, Cassidy J, et al: Polymorphism in the thymidylate synthase promoter enhancer region in colorectal cancer. Int J Oncol 19:383-386, 2001
21. Salonga D, Danenberg KD, Johnson M, et al: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyridine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6:1322-1327, 2000
22. Villafranca E, Okruzhnov Y, Dominguez MA, et al: Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J Clin Oncol 19:1779-1786, 2001
23. Metzger R, Danenberg K, Leichman CG, et al: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 4:2371-2376, 1998
24. Meropol NJ, Gold PJ, Diasio RB, et al: Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 24(25):4069-4077, 2006
25. Burris HA 3rd, Moore MJ, Andersen J, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15(6): 2403-2413, 1997
26. Plunkett W, Huang P, Xu YZ, et al: Gemcitabine: metabolism, mechanisms of action, and selfpotentiation. Semin Oncol 22:3-10, 1995
27. Gandhi V, Plunkett W: Modulatory activity of 2?,2?-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res 50:3675-3680, 1990
28. Spratlin J, Sangha R, Glubrecht D, et al: The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10:6956-6961, 2004
29. Mackey JR, Mani RS, Selner M, et al: Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58:4349-4357, 1998
30. Sebastiani V, Ricci F, Rubio-Viqueira B, et al: Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12:2492-2497, 2006
31. Giovannetti E, Mey V, Nannizzi S, et al: Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol Cancer Ther 5:1387-1395, 2006
32. Bergman AM, Pinedo HM, Peters GJ: Determinants of resistance to 2?,2?-difluorodeoxycytidine (gemcitabine). Drug Resist Update 5: 19-33, 2002
33. Mini E, Nobili S, Caciagli B, et al: Cellular pharmacology of gemcitabine. Ann Oncol 17 (suppl 5):v7-v12, 2006
34. Ueno H, Kiyosawa K, Kaniwa N: Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer 97:145-151, 2007
35. Yonemori K, Ueno H, Okusaka T, et al: Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin. Clin Cancer Res 11: 2620-2624, 2005
36. Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24:4731-4737, 2006
37. Mathijssen RH, van Alphen RJ, Verweij J, et al: Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 7:2182-2194, 2001
38. Charasson V, Bellott R, Meynard D, et al: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin Pharmacol Ther 76:528-535, 2004
39. Khanna R, Morton C, Danks MK, et al: Proficient metabolism of irinotecan by a human intestinal carboylesterase. Cancer Res 60: 4725-4728, 2000
40. Innocenti F, Undevia SD, Iyer L, et al: Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382, 2004
41. Iyer L, Das S, Janisch L, et al: UGT1A1*28 polimorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47, 2002
42. Hoskins J, Goldberg R, Qu P, et al: UGT1A1*28 genotype and irinotecan induced neutropenia: dose matters. J Natl Cancer Inst 99: 1290-1295, 2007
43. McLeod, HL, Sargent DJ, Marsh S, et al: Pharmacogenetic analysis of systemic toxicity and response after 5-fluorouracil (5FU)/CPT-11, 5FU/oxaliplatin (oxal), or CPT-11/oxal therapy for advanced colorectal cancer (CRC): Results from an intergroup trial. Proc Am Soc Clin Oncol 22:2003 (abstr 1013)
44. Vermorken JB, van der Vijgh WJF, Klein I, et al: Pharmacokinetics of free and total platinum species after short infusion of cisplatin. Cancer Treat Rep 68:505-513, 1984
45. Raymond E, Faivre S, Woynarowski JM, et al: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25(2 suppl 5): 4-12, 1998
46. Levi F, Metzger G, Massari C, et al: Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin Pharmacokinet 5:1-21, 2000
47. Ruzzo A, Graziano F, Loupakis F, et al: Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247-1254, 2007
48. Stoehlmacher J, Park DJ, Zhang W, et al: A multivariate analysis of genomic polymorphisms: Prediction of clinical outcome to 5-fluorouracil/ oxaliplatin combination chemotherapy in refractory colorectal cancer. Br J Cancer 91:344-354, 2004
49. Goldberg RM, McLeod HL, Sargent DJ, et al: Genetic polymorphisms, toxicity, and response rate in African Americans (AA) with metastatic colorectal cancer (MCRC) compared to Caucasians (C) when treated with IFL, FOLFOX or IROX in Intergroup N9741. J Clin Oncol 24(18S June 20 suppl):2006 (abstr 3503)
50. Grothey A, McLeod HL, Green EM, et al: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity. J Clin Oncol 23(16S June 1 suppl):2005 (abstr 3509)
51. Viguier J, Boige V, Miquel C, et al: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin Cancer Res 11:6212-6217, 2005
52. Lenz H, Zhang W, Yang D, et al: Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. 2007 Gastrointestinal Cancers Symposium (abstr 401)
53. Zhang W, Vallböhmer D, Yang D, et al: Genomic profile associated with clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab. J Clin Oncol 23(16S June 1 suppl):2005 (abstr 3557)
54. Zhang W, Yang D, Capanu M, et al: Pharmacogenomic analysis of a randomized phase II trial (BOND 2) of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. J Clin Oncol 25(18S June 20 suppl):2007 (abstr 4128)
55. Van Cutsem E, Lang I, D'haens G, et al: KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 26(15S May 20 suppl):5s, 2008 (abstr 2)
56. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
57. Bokemeyer C, Bondarenko I, Hartmann J, et al: KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 26(15S May 20 suppl):178s, 2008 (abstr 4000)
58. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
59. Di Fiore F, Van Cutsem E, Laurent-Puig P, et al: Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. J Clin Oncol 26(15S May 20 suppl):2008 (abstr 4035)
60. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
61. Li J, Zhao M, He P, et al: Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes. Clin Cancer Res 13:3731-3737, 2007
62. Rudin CM, Liu W, Desai A, et al: Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity. J Clin Oncol 26:1119-1127, 2008
63. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966, 2007
64. Moore MJ, da Cunha Santos G, Kamel-Reid S: The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3. J Clin Oncol 25(18S June 20 suppl):2007 (abstr 4521)
65. Verslype C, Vervenne W, Bennouna J, et al: Rash as a marker for the efficacy of gemcitabine plus erlotinib-based therapy in pancreatic cancer: Results from the AViTA Study. Rash as a marker for the efficacy of gemcitabine plus erlotinibbased therapy in pancreatic cancer: Results from the AViTA Study. J Clin Oncol 27(15S suppl):2009 (abstr 4532)